Treatment of experimental colitis by endometrial regenerative cells through regulation of B lymphocytes in mice
Open Access
- 22 May 2018
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 9 (1) , 146
Abstract
Endometrial regenerative cells (ERCs), a novel type of mesenchymal-like stem cell derived from menstrual blood, have been recently evaluated as an attractive candidate source in ulcerative colitis (UC); however, the mechanism is not fully understood. The present study was designed to investigate the effects of ERCs, especially on B-cell responses in UC. In this study, colitis was induced by administering 3% dextran sodium sulfate (DSS) via free drinking water for 7 days to BALB/c mice. In the treated group, mice were injected intravenously with 1 × 106 ERCs on days 2, 5, and 8 after DSS induction. Therapeutic effects were assessed by monitoring body weight, disease activity, and pathological changes. Subpopulations of lymphocytes were determined by flow cytometry. IgG deposition in the colon was examined by immunohistochemistry staining. Cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA), Western blot, or polymerase chain reaction (PCR) analysis. Adoptive transfer of regulatory B cells (Bregs) into colitis mice was performed. Here, we demonstrated that ERC treatment prolonged the survival of colitis mice and attenuated disease activity with fewer pathological changes in colon tissue. ERCs decreased the proportion of immature plasma cells in the spleen and IgG deposition in the colon. On the other hand, ERCs increased the production of Bregs and the interleukin (IL)-10 level. Additionally, adoptive transferred Bregs exhibited significant therapeutic effects on colitis mice. In conclusion, our results unravel the therapeutic role of ERCs on experimental colitis through regulating the B-lymphocyte responses.Keywords
Funding Information
- National Natural Science Foundation of China (81273257, 81471584)
- Tianjin Application Basis and Cutting-Edge Technology Research Grant (14JCZDJC35700)
- Li Jieshou Intestinal Barrier Research Special Fund (LJS_201412)
This publication has 46 references indexed in Scilit:
- Stromal Cell-Derived Factor-1 Mediates Cardiac Allograft Tolerance Induced by Human Endometrial Regenerative Cell-Based TherapyStem Cells Translational Medicine, 2017
- Therapeutic Potential of Secreted Molecules Derived from Human Amniotic Fluid Mesenchymal Stem/Stroma Cells in a Mice Model of ColitisStem Cell Reviews and Reports, 2016
- Interleukin 10 Receptor Signaling2014
- Conditioned mesenchymal stem cells produce pleiotropic gut trophic factorsJournal of Gastroenterology, 2013
- B Cells Exposed to Enterobacterial Components Suppress Development of Experimental ColitisInflammatory Bowel Diseases, 2012
- IL-10–Producing Regulatory B10 Cells Inhibit Intestinal Injury in a Mouse ModelThe American Journal of Pathology, 2011
- B‐cell depletion with anti‐CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor‐β receptor II dominant negative mice†Hepatology, 2009
- Mesenchymal stem cells suppress B-cell terminal differentiationExperimental Hematology, 2009
- Exacerbation of ulcerative colitis after rituximab salvage therapyInflammatory Bowel Diseases, 2007
- The B-Cell System in Inflammatory Bowel Disease2006